CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 130 enrolled
Drug / intervention
enzastaurin +1 moredrug
Likely dose
enzastaurin 1200 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00267020
NCT00267020Phase 2Completed
CompareCT.gov

A Randomized, Open-Label Phase 2 Study of 2 Regimens, Gemcitabine Plus Enzastaurin and Single-Agent Gemcitabine, in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Eli Lilly and Company·interventional·Posted Dec 20, 2005·Updated Aug 31, 2020

In Brief

A Phase 2 clinical trial evaluating enzastaurin and gemcitabine for Pancreatic Neoplasm. Completed, enrolled 130 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine the effects and toxicity of gemcitabine alone or gemcitabine plus enzastaurin in participants with pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Neoplasm
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2005
Enrollment StartDec 1, 2005
Primary CompletionMay 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.5 years ago

Interventions

enzastaurindrug

1200 milligrams (mg) loading dose then 500 mg, orally, daily, six 28-day cycles

gemcitabinedrug

1000 milligrams/square meter (mg/m\^2), intravenously on Days 1, 8 and 15 per cycle, six 28-day cycles